Stocktoria
Stoke Therapeutics, Inc. STOK
Stoke Therapeutics, Inc. (STOK) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $184.4M at a -3.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.592 |
| Retained earnings / assets | -1.189 |
| EBIT / assets | -0.049 |
| Equity / liabilities | 5.342 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | 4/9 | 5.29 | — | +404.5% |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | 1/9 | 1.29 | — | -28.3% |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | 5/9 | -6.24 | — | +45.8% |
| CYRX | Cryoport, Inc. | 4/9 | 0.96 | 10.3 | +12.4% |
| PHAT | Phathom Pharmaceuticals, Inc. | 4/9 | — | — | +216.9% |
| SNDX | Syndax Pharmaceuticals Inc | 1/9 | -7.54 | — | +627.8% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
FAQ
Is STOK financially healthy?
Stoke Therapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does STOK pay a dividend?
No, Stoke Therapeutics, Inc. does not currently pay a dividend.
How profitable is STOK?
In FY2025, Stoke Therapeutics, Inc. had a net margin of -3.7% and a return on equity of -2.0%.
What is the analyst price target for STOK?
The average Wall-Street price target for Stoke Therapeutics, Inc. is $45.10, about 36.8% above the recent price, from 10 analysts (consensus: strong buy).
Is STOK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Stoke Therapeutics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.